Henry Masur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Henry Masur has a total of 513 co-authors. Here are the top co-authors by number of shared publications:
Jonathan E. Kaplan
Centers for Disease Control and Prevention , Atlanta, Georgia
4 shared publications- Joseph A. Kovacs
Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA
4 shared publications King K. Holmes
University of Washington , Seattle
4 shared publicationsAndre C Kalil
University of Nebraska Medical Center, Omaha
2 shared publicationsAnthony F. Suffredini
National Institutes of Health, Bethesda, Maryland, USA
2 shared publications- Charles Robert Horsburgh
Department of Epidemiology, Boston University School of Public Health , Boston, Massachusetts
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Continuum of care in hospitalized patients with opioid or stimulant use disorder and infectious complications of drug use—substance use/infectious disease integrated clinic compared to treatment as usual to prevent infection-related readmission (CHOICE-STAR): a study protocol for an effectiveness-implementation randomized controlled trial
People who inject drugs (PWID) experience high rates of serious injection-related bacterial and fungal infections (SIRI), including cellulitis, osteomyelitis, and endocarditis. These infections often require prolonged antibiotic treatment and result in frequent rehospitalizations, with over 50% of patients readmitted within 1 year. Few evidence-based interventions exist to optimize continuity of care for addiction, management, and prevention of SIRI following hospitalization. CHOICE-STAR is a hybrid type 1 randomized effectiveness-implementation trial, guided by the Exploration, Preparation, Implementation, and Sustainment Framework (EPIS), conducted at five hospitals across the USA. The study aims to assess the effectiveness of the integrated infectious diseases (ID) and substance use disorder (SUD) outpatient clinic on 6-month infection-related rehospitalization among people hospitalized with an infection related to injecting opioids or stimulants. The study also includes implementation outcomes guided by Proctor's Implementation Outcomes taxonomy, as well as cost-effectiveness outcomes. The integrated clinic (IC) will offer facilitated linkage to a clinic providing medical care aimed at treating SUD and ID by completing treatment for the index infection, treating existing ID complications of SUD, and preventing subsequent infections by providing low barrier care for SUD including medication for OUD (MOUD) and harm reduction integrated into a single appointment and co-located at a single site for a minimum of monthly appointments over a 6 month time period. An additional 6 months' follow-up will be included to assess outcomes following the completion of the intervention. The IC includes a weekly care coordination meeting between the ID and SUD providers. The study will enroll approximately 304 participants. This trial addresses a critical gap in post-hospitalization care for PWID with SIRI. If effective, the integrated care model could significantly reduce rehospitalizations, improve treatment completion, and provide a replicable framework for healthcare systems. The study's implementation science components will inform the scalability and sustainability of this intervention. Results will inform evidence-based policy and practice recommendations for managing this high-risk population, potentially leading to improved patient health outcomes. ClinicalTrials.gov NCT06513156. Registered on August 09, 2024.
- 4 March 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessContinuum of care in hospitalized patients with opioid or stimulant use disorder and infectious complications of drug use—substance use/infectious disease integrated clinic compared to treatment as usual to prevent infection-related readmission (CHOICE-STAR): a study protocol for an effectiveness-implementation randomized controlled trial
People who inject drugs (PWID) experience high rates of serious injection-related bacterial and fungal infections (SIRI), including cellulitis, osteomyelitis, and endocarditis. These infections often require prolonged antibiotic treatment and result in frequent rehospitalizations, with over 50% of patients readmitted within 1 year. Few evidence-based interventions exist to optimize continuity of care for addiction, management, and prevention of SIRI following hospitalization. CHOICE-STAR is a hybrid type 1 randomized effectiveness-implementation trial, guided by the Exploration, Preparation, Implementation, and Sustainment Framework (EPIS), conducted at five hospitals across the USA. The study aims to assess the effectiveness of the integrated infectious diseases (ID) and substance use disorder (SUD) outpatient clinic on 6-month infection-related rehospitalization among people hospitalized with an infection related to injecting opioids or stimulants. The study also includes implementation outcomes guided by Proctor's Implementation Outcomes taxonomy, as well as cost-effectiveness outcomes. The integrated clinic (IC) will offer facilitated linkage to a clinic providing medical care aimed at treating SUD and ID by completing treatment for the index infection, treating existing ID complications of SUD, and preventing subsequent infections by providing low barrier care for SUD including medication for OUD (MOUD) and harm reduction integrated into a single appointment and co-located at a single site for a minimum of monthly appointments over a 6 month time period. An additional 6 months' follow-up will be included to assess outcomes following the completion of the intervention. The IC includes a weekly care coordination meeting between the ID and SUD providers. The study will enroll approximately 304 participants. This trial addresses a critical gap in post-hospitalization care for PWID with SIRI. If effective, the integrated care model could significantly reduce rehospitalizations, improve treatment completion, and provide a replicable framework for healthcare systems. The study's implementation science components will inform the scalability and sustainability of this intervention. Results will inform evidence-based policy and practice recommendations for managing this high-risk population, potentially leading to improved patient health outcomes. ClinicalTrials.gov NCT06513156. Registered on August 09, 2024.
- Open Access
- 31 August 2024
- Published by Springer Nature
- p. 531-547
20 Turning Research Results into Clinical Practice Guidelines in Public Health Emergencies
Clinical practice guidelines (CPGs) assist clinicians with medical decision making for diagnosis, prevention, and management of medical conditions. Traditional CPGs for established diseases generally follow a lengthy process during which robust, peer-reviewed published data are used to formulate recommendations in a CPG panel. In public health challenges such as HIV and hepatitis C, a different paradigm is necessary. HIV and hepatitis C are areas in which changing data emerged rapidly, and as such CPGs needed to be done carefully but quickly. The magnitude of the coronavirus disease 2019 (COVID-19) public health emergency, the rapid emergence of important new epidemiologic and clinical data, the availability of an immense amount of information from non-peer-reviewed sources such as the Internet, social media platforms, and pre-prints, along with public expectations for current and objective advice regarding prevention and treatment of COVID-19, warranted the creation of an emergency CPG panel that was quite different from any previous CPG, including those for HIV and hepatitis C. For healthcare practitioners, public health officials, and other stakeholders, there are many lessons to be learned here about the creation of CPGs that can rapidly provide much-needed guidance in a credible, current, understandable format, which can have a major impact on healthcare, patient outcomes, and the trajectory of an epidemic or pandemic.
- 31 August 2024
- Published by Springer Nature
- p. 531-547
Open Access20 Turning Research Results into Clinical Practice Guidelines in Public Health Emergencies
Clinical practice guidelines (CPGs) assist clinicians with medical decision making for diagnosis, prevention, and management of medical conditions. Traditional CPGs for established diseases generally follow a lengthy process during which robust, peer-reviewed published data are used to formulate recommendations in a CPG panel. In public health challenges such as HIV and hepatitis C, a different paradigm is necessary. HIV and hepatitis C are areas in which changing data emerged rapidly, and as such CPGs needed to be done carefully but quickly. The magnitude of the coronavirus disease 2019 (COVID-19) public health emergency, the rapid emergence of important new epidemiologic and clinical data, the availability of an immense amount of information from non-peer-reviewed sources such as the Internet, social media platforms, and pre-prints, along with public expectations for current and objective advice regarding prevention and treatment of COVID-19, warranted the creation of an emergency CPG panel that was quite different from any previous CPG, including those for HIV and hepatitis C. For healthcare practitioners, public health officials, and other stakeholders, there are many lessons to be learned here about the creation of CPGs that can rapidly provide much-needed guidance in a credible, current, understandable format, which can have a major impact on healthcare, patient outcomes, and the trajectory of an epidemic or pandemic.
- Open Access
CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients
Liver fibrosis is accelerated in patients coinfected with hepatitis C virus and human immunodeficiency virus (HIV), compared with HCV monoinfected patients, although the underlying mechanisms are unknown. We hypothesize that T cells expressing the HIV co-receptor, chemokine receptor 5 (CCR5), preferentially migrate to the inflamed liver and contribute to enhanced fibrogenesis. We compared the peripheral and intrahepatic CCR5 expression on CD4+ and CD8+ T cells in 21 HIV/HCV-coinfected patients with 14 chronic HCV monoinfected patients. Using 12-color flow cytometry, phenotypic and functional characterization of CCR5+ and negative cells pre- and post-stimulation with HCV genotype specific overlapping pooled peptides was conducted. Patients with HIV/HCV coinfection had significantly more CD4+CCR5+ and CD8+CCR5+ T cells in the liver as compared with peripheral blood (p = 0.0001 for both). Compared with patients with HCV monoinfection, patients with HIV/HCV coinfection also had fewer peripheral CD4+CCR5+ and CD8+CCR5+ T cells (p = 0.02, p = 0.001 respectively), but more intrahepatic CD4+CCR5+ and CD8+CCR5+ cells (p = 0.0001 for both). Phenotypic analysis of CCR5+ sorted cells demonstrated an increased expression of markers of exhaustion, senescence, immune activation and liver homing (PD1, CD57, CD38, HLADR, and CXCR3). Post-stimulation with HCV peptides, CCR5+ T cells secreted more proinflammatory and profibrogenic cytokines and chemokines rather than antiviral cytokines. Phenotypic and functional analyses of CCR5+ T cells in HIV/HCV-coinfected patients revealed a pathogenic role for CCR5+ T cells in hepatic fibrogenesis. These cells are functionally proinflammatory, pro-fibrogenic and preferentially accumulate in liver, accelerating fibrosis. These findings suggest that targeting CCR5 may be a therapeutic strategy for be ameliorating liver fibrosis.
Open AccessCCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients
Liver fibrosis is accelerated in patients coinfected with hepatitis C virus and human immunodeficiency virus (HIV), compared with HCV monoinfected patients, although the underlying mechanisms are unknown. We hypothesize that T cells expressing the HIV co-receptor, chemokine receptor 5 (CCR5), preferentially migrate to the inflamed liver and contribute to enhanced fibrogenesis. We compared the peripheral and intrahepatic CCR5 expression on CD4+ and CD8+ T cells in 21 HIV/HCV-coinfected patients with 14 chronic HCV monoinfected patients. Using 12-color flow cytometry, phenotypic and functional characterization of CCR5+ and negative cells pre- and post-stimulation with HCV genotype specific overlapping pooled peptides was conducted. Patients with HIV/HCV coinfection had significantly more CD4+CCR5+ and CD8+CCR5+ T cells in the liver as compared with peripheral blood (p = 0.0001 for both). Compared with patients with HCV monoinfection, patients with HIV/HCV coinfection also had fewer peripheral CD4+CCR5+ and CD8+CCR5+ T cells (p = 0.02, p = 0.001 respectively), but more intrahepatic CD4+CCR5+ and CD8+CCR5+ cells (p = 0.0001 for both). Phenotypic analysis of CCR5+ sorted cells demonstrated an increased expression of markers of exhaustion, senescence, immune activation and liver homing (PD1, CD57, CD38, HLADR, and CXCR3). Post-stimulation with HCV peptides, CCR5+ T cells secreted more proinflammatory and profibrogenic cytokines and chemokines rather than antiviral cytokines. Phenotypic and functional analyses of CCR5+ T cells in HIV/HCV-coinfected patients revealed a pathogenic role for CCR5+ T cells in hepatic fibrogenesis. These cells are functionally proinflammatory, pro-fibrogenic and preferentially accumulate in liver, accelerating fibrosis. These findings suggest that targeting CCR5 may be a therapeutic strategy for be ameliorating liver fibrosis.
- Open Access
- 9 August 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (8) , 1432
Reply to Al-Hasan and Justo
- 9 August 2018
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (8) , 1432
Open AccessReply to Al-Hasan and Justo
- Open Access
- 22 November 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (10) , 1631-1635
Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines
The Infectious Diseases Society of America elected not to endorse the Surviving Sepsis Campaign Guidelines due to lack of agreement with the Society of Critical Care Medicine regarding specific recommendations related to diagnosis and therapy for patients with apparent or documented sepsis/septic shock.
- 22 November 2017
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (10) , 1631-1635
Open AccessInfectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines
The Infectious Diseases Society of America elected not to endorse the Surviving Sepsis Campaign Guidelines due to lack of agreement with the Society of Critical Care Medicine regarding specific recommendations related to diagnosis and therapy for patients with apparent or documented sepsis/septic shock.
- Open Access
- 3 June 2015
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 212 (9) , 1348-1350
Opportunistic Infections and Mortality: Still Room for Improvement
(See the major article by Djawe et al on pages 1366–75.)
- 3 June 2015
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 212 (9) , 1348-1350
Open AccessOpportunistic Infections and Mortality: Still Room for Improvement
(See the major article by Djawe et al on pages 1366–75.)
- Top Cited PapersOpen Access
- 27 February 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (9) , 1308-1311
Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America
The CDC/NIH/HIVMA Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have been revised. Major areas of revision include immune reconstitution inflammatory syndrome, tuberculosis, hepatitis B virus, hepatitis C virus, human papillomavirus, and immunizations. In May 2013, a revised and updated version of the Centers for Disease Control and Prevention/National Institutes of Health/HIV Medicine Association Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was released online. These guidelines, since their inception in 1989, have been widely accessed in the United States and abroad. These guidelines have focused on the management of HIV/AIDS-related opportunistic infections that occur in the United States. In other parts of the world, the spectrum of complications may be different and the resources available for diagnosis and management may not be identical to those in the United States. The sections that have been most extensively updated are those on immune reconstitution inflammatory syndrome, tuberculosis, hepatitis B, hepatitis C, human papillomavirus, and immunizations. The guidelines will not be published in hard copy form. This document will be revised as needed throughout each year as new data become available.
- 27 February 2014
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (9) , 1308-1311
Top Cited PapersOpen AccessPrevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Updated Guidelines From the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America
The CDC/NIH/HIVMA Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have been revised. Major areas of revision include immune reconstitution inflammatory syndrome, tuberculosis, hepatitis B virus, hepatitis C virus, human papillomavirus, and immunizations. In May 2013, a revised and updated version of the Centers for Disease Control and Prevention/National Institutes of Health/HIV Medicine Association Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was released online. These guidelines, since their inception in 1989, have been widely accessed in the United States and abroad. These guidelines have focused on the management of HIV/AIDS-related opportunistic infections that occur in the United States. In other parts of the world, the spectrum of complications may be different and the resources available for diagnosis and management may not be identical to those in the United States. The sections that have been most extensively updated are those on immune reconstitution inflammatory syndrome, tuberculosis, hepatitis B, hepatitis C, human papillomavirus, and immunizations. The guidelines will not be published in hard copy form. This document will be revised as needed throughout each year as new data become available.
- 1 December 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (12) , 3277-3282
Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit
Healthcare systems spend considerable resources collecting and processing blood cultures for the detection of blood stream pathogens. The process is initiated with the collection of blood cultures that depend upon proper skin disinfection, collection of an adequate number of specimens and volume of blood, and prompt processing in a sensitive culture system. Complementing blood cultures and gaining in use are techniques such as nucleic acid amplification tests and mass spectroscopy that allow clinical laboratories to detect and identify organisms from blood cultures substantially faster than conventional systems. Furthermore, certain resistance mutations can be detected within hours of organism detection, thus providing valuable guidance to clinicians who strive to initiate the appropriate antimicrobial therapy as rapidly as possible, and who wish to discontinue unnecessary drugs expeditiously. Molecular and mass spectroscopy techniques are changing sepsis diagnosis rapidly and will provide far more specific information far more quickly, but the performance characteristics of these systems must be understood by intensivists who use such information to guide their patient management.
- 1 December 2012
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 40 (12) , 3277-3282
Current approaches to the diagnosis of bacterial and fungal bloodstream infections in the intensive care unit
Healthcare systems spend considerable resources collecting and processing blood cultures for the detection of blood stream pathogens. The process is initiated with the collection of blood cultures that depend upon proper skin disinfection, collection of an adequate number of specimens and volume of blood, and prompt processing in a sensitive culture system. Complementing blood cultures and gaining in use are techniques such as nucleic acid amplification tests and mass spectroscopy that allow clinical laboratories to detect and identify organisms from blood cultures substantially faster than conventional systems. Furthermore, certain resistance mutations can be detected within hours of organism detection, thus providing valuable guidance to clinicians who strive to initiate the appropriate antimicrobial therapy as rapidly as possible, and who wish to discontinue unnecessary drugs expeditiously. Molecular and mass spectroscopy techniques are changing sepsis diagnosis rapidly and will provide far more specific information far more quickly, but the performance characteristics of these systems must be understood by intensivists who use such information to guide their patient management.
- 31 July 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (12) , 1849-1855
Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa
Objective: To determine important risk factors for and impact of tuberculosis on survival in HIV-infected patients starting antiretroviral therapy (ART) in South Africa. Design: Prospective trial of 1771 HIV-infected patients with either CD4 cell count less than 200 cells/μl or a prior AIDS-defining illness, enrolled in randomized trial of four antiretroviral regimens. Methods: Data collected from patient records. Results: A history of tuberculosis at study entry was reported by 27% of patients and correlated with poor baseline health status. A history of tuberculosis at baseline was associated with subsequent tuberculosis and death during ART, but was not itself an independent risk factor for poor outcome. Tuberculosis was diagnosed during ART in 14% of patients and was more frequent during the first 3 months. Tuberculosis during therapy was independently associated with increased hazard of other AIDS-defining events and death, regardless of when during ART tuberculosis occurred. ART that consistently suppressed circulating viremia reduced but did not eliminate tuberculosis risk. Conclusion: In HIV-infected patients who started ART at low CD4 cell counts, tuberculosis at baseline was a predictor of death, but was not independent of other factors indicating poor baseline health status. Tuberculosis during follow-up was, in contrast, an independent predictor of death even after adjustments for baseline risk factors, including CD4 cell count and viral load. Virologic failure during ART was associated with a 55% increase in risk of tuberculosis. Thus, tuberculosis is a major marker for poor outcome both at baseline and during ART and is not completely eliminated by fully suppressive ART.
- 31 July 2010
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (12) , 1849-1855
Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa
Objective: To determine important risk factors for and impact of tuberculosis on survival in HIV-infected patients starting antiretroviral therapy (ART) in South Africa. Design: Prospective trial of 1771 HIV-infected patients with either CD4 cell count less than 200 cells/μl or a prior AIDS-defining illness, enrolled in randomized trial of four antiretroviral regimens. Methods: Data collected from patient records. Results: A history of tuberculosis at study entry was reported by 27% of patients and correlated with poor baseline health status. A history of tuberculosis at baseline was associated with subsequent tuberculosis and death during ART, but was not itself an independent risk factor for poor outcome. Tuberculosis was diagnosed during ART in 14% of patients and was more frequent during the first 3 months. Tuberculosis during therapy was independently associated with increased hazard of other AIDS-defining events and death, regardless of when during ART tuberculosis occurred. ART that consistently suppressed circulating viremia reduced but did not eliminate tuberculosis risk. Conclusion: In HIV-infected patients who started ART at low CD4 cell counts, tuberculosis at baseline was a predictor of death, but was not independent of other factors indicating poor baseline health status. Tuberculosis during follow-up was, in contrast, an independent predictor of death even after adjustments for baseline risk factors, including CD4 cell count and viral load. Virologic failure during ART was associated with a 55% increase in risk of tuberculosis. Thus, tuberculosis is a major marker for poor outcome both at baseline and during ART and is not completely eliminated by fully suppressive ART.